Pursuant to the provisions of Regulation 30 read with Schedule III Part A Para B of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the SEBI circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026, Cipla has informed that the Cipla USA Inc., wholly owned subsidiary of the Company in USA (referred as ‘Cipla’) has received final approval from the United States Food and Drug Administration (‘USFDA’) for the Abbreviated New Drug Application (‘ANDA’) submitted for Albuterol Sulfate Inhalation Aerosol, 90 mcg per actuation, the first AB rated generic therapeutic equivalent of Ventolin® HFA, marketed by GlaxoSmithKline. Albuterol Sulfate Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in adult and pediatric patients aged four years and older with reversible obstructive airway disease, as well as for the prevention of exercise induced bronchospasm in patients aged four years and older. The product is expected to be launched in H1 of FY 2026-27 in the United States of America. A press release dated 23rd April 2026 is also enclosed.